Nuclidium

Nuclidium is a Swiss-German biotech focused on disrupting the radiopharmaceutical space with its proprietary copper-based theranostic platform. By utilizing Copper-61 and Copper-67 isotopes paired with the same targeting molecule, the company aims to overcome key limitations in current radiotheranostics, such as mismatched diagnostics/therapeutics and complex supply chains, to enable more accurate and accessible cancer treatment. Founded in 2019, the company is advancing a pipeline targeting major solid tumors and has established a secured production process and distribution network. It operates as a private, clinical-stage entity seeking to set a new standard in precision oncology.

Copper-based radiotheranostic platform utilizing Copper-61 for diagnostic PET imaging and Copper-67 for targeted radiotherapy, paired with the same targeting molecule for perfect pharmacokinetic matching.

Nuclidium competes in the dynamic radiotheranostics space against large pharmaceutical companies (e.g., Novartis with Pluvicto, Bayer) and numerous biotechs developing platforms based on isotopes like Lutetium-177, Actinium-225, and Terbium-161. Its differentiation hinges on proving the clinical and economic advantages of its matched-pair copper system.